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Abbreviations: 
BE = balloon expandable. 
BMS = bare metal stent.  
BP = blood pressure.  
CIA = common iliac artery.   
CKD = chronic kidney disease. 
CTO = chronic total occlusion 
DCB = drug coated balloon.  
DES = drug eluting stent.  
EIA = external iliac artery.   
EVT = endovascular therapy. 
FP = femoral-popliteal. 
GDMT = guideline directed medical therapy.  
HTN = hypertension. IP = infra-popliteal.   
LASER = light amplification by stimulated emission of radiation. 
PFA = profunda femoris artery.   
PVAD = percutaneous ventricular assist device. 
PTA = percutaneous transluminal angioplasty. 
RAS = renal artery stenosis.  
RC = Rutherford classification.   
SE = self-expanding. 
TAVR = transcatheter aortic valve replacement.  
TLR = target lesion revascularization 
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Introduction 
In 2014, the Society for Cardiovascular Angiography and Interventions (SCAI) published the 
first Appropriate Use Criteria (AUC) for endovascular therapy (EVT) for atherosclerotic peripheral 
artery disease (PAD) involving the aorto-iliac, femoral-popliteal, infra-popliteal and renal arterial 
circulations. 1-4 These documents were developed to assist clinicians' decision-making, to improve 
patients' understanding regarding relative risks and benefits of a procedure, and to guide future 
research.  Clinical scenarios were described in which catheter-based intervention was classified as 
“appropriate,” “may be appropriate,” or “rarely appropriate”, incorporating the best clinical and 
scientific evidence, cost-effectiveness data and the consensus of experts within the SCAI Peripheral 
Vascular Disease Committee.   
The purpose of this update is to provide a focused review of new clinical evidence regarding 
EVT, to identify novel technologies and practice changes that have been introduced since the 
original documents were published and to provide updated recommendations. 
 
Methodology 
 The definition of appropriate use (AUC) is largely consistent across technologies and 
procedures.  AUC considers the risks and benefits of a procedure while applying this balance across 
clinically relevant scenarios. An appropriate diagnostic or therapeutic procedure is one in which 
the expected clinical benefit exceeds the risks of the procedure by a sufficiently wide margin such 
that the procedure is generally considered acceptable or reasonable. 5,6   
Experts were nominated and selected based upon their intellectual integrity and expertise 
with consideration of industry and intellectual bias. The writing group members are familiar with 
the application of the techniques and strategies under consideration to ensure that the clinical 
scenarios were constructed to capture the clinical applicability and limitations of the therapies.   
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 In general, the SCAI modified Delphi panel methodology employed an expert panel of 
clinicians who rated a series of clinical scenarios on a nine-point scale (Appropriate 7-9, May Be 
Appropriate 4-6, and Rarely Appropriate 1-3). The panel participated in a minimum of three rounds 
of ratings, with communication among the panelists after the first round. Each panelist had equal 
weight in determining the final rating. A synthesis of the updated scientific literature was prepared 
for each anatomical area for review by the rating panel.  After review of the updated literature, 
panelists were asked to review each clinical scenario and to score it. Agreement among panelists 
was achieved when none of the ratings for any of the scenarios fell outside the 2-point margin of the 
mean score.  
 For renal arterial revascularization, the benefits included: blood pressure improvement, 
renal function improvement or stabilization, and improved cardiac destabilization syndromes 
(heart failure and angina exacerbations) weighed against the risks of the procedure. For lower 
extremity arterial revascularization, the benefits included: survival or health outcomes such as 
symptom improvement, limb salvage, functional status and/or quality of life, weighed against the 
risks of the procedure.   
 "Appropriate Care" implies that the benefits generally outweigh the risks of the procedure. 
The procedure is an effective option for individual care although not always required or necessary; 
the procedure is generally acceptable and reasonable for the indication.   
 "May Be Appropriate Care" describes an option that is generally accepted with variable 
levels of supporting evidence or expert consensus regarding the risk to benefit ratio.  There may be 
utility in selected cases based upon clinical experience in the absence of comparative evidence.  The 
appropriateness of a specific procedure in any individual must be determined by that patient’s 
physician in consultation with the patient considering the risk to benefit ratio. This category of 
procedures may be acceptable and may be reasonable for the clinical scenario.   
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 "Rarely Appropriate" care describes an option for the management of a patient with an 
adverse or uncertain risk to benefit ratio.  The option is not commonly used as an effective therapy 
and the rationale for choosing this option needs to be documented.  The procedure is recognized to 
be effective in selected situations but is not generally applied and is not generally reasonable for the 
indication.  Procedures in this category require justification through the documentation of 
individual patient circumstances.  
 
AUC Methodology and Assumptions 
1. The clinical scenarios chosen for this document are not intended to be all-inclusive.  Not 
every clinical scenario can or will be addressed.   
2. Lesion characteristics are arbitrarily divided into focal, intermediate, and diffuse for each 
anatomical subset as defined below.  
3. When not specifically stated, assume that patients are being treated with guideline-directed 
medical therapy (GDMT). 
4. Scenarios were scored independently of each other.  There is no "ranking" of indications.  
This means that two different scenarios regarding aorto-iliac intervention may be scored 
the same value (i.e. 7 (appropriate), even if the scenarios are different.  
5. The cost of care was considered in determining appropriateness.  For example, a procedure 
that is ten-times more expensive than another, but equally effective, should be rated lower.  
Devi e cost, complication rates, durable patency and length of hospital stay all contribute to 
the cost of care. 
6. It is assumed that interventions are performed by the "average" interventionalist, who is 
credentialed by their hospital to perform the procedure being considered, and not the most 
experienced expert, nor the most recent graduate from fellowship training. In each of the 
depicted clinical scenarios, the assumption is made that the approach to EVT was carefully 
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considered in terms of the clinical need, the opportunity for benefit, as well as the potential 
risks.   
7. For device scenarios, assume the intention is to use the device as the ultimate or definitive 
device, regardless of lesion preparation.  Percutaneous transluminal angioplasty (PTA) can 
be chosen as the intended definitive treatment, even if it may be necessary to “bail out” with 
a stent.  DCB can be chosen as the intended definitive treatment with the knowledge the 
lesion will be prepared and pre-dilated with an uncoated balloon first.  Rotational 
atherectomy can be considered as the definitive treatment modality if the procedure could 
not be completed without its use, an undilatable lesions for example, despite the need for 
subsequent PTA or stent placement to complete the procedure. 
8. Rarely Appropriate (1 - 3) means that a particular procedure will be appropriate only in 
selected circumstances.  It does not mean "never", although a score of 1 (one) is as close to 
never as one can get.  
9. May Be Appropriate (4 - 6) means that a procedure is indicated under certain 
circumstances, and not in others. 
10. Appropriate (7 - 9) means that a procedure is usually indicated, with a score of 9 (nine) 
representing usual care. 
 
 General Definitions 
1. Occlusion describes complete cessation of flow through the arterial segment. 
2. Provisional stenting implies PTA with bail-out stent placement if a flow-limiting dissection 
or significant residual stenosis occurs.  
3. Primary stenting implies the intention to place a stent regardless of the outcome of any pre-
dilation or pre-treatment.   
4. Multiple lesions are more than one focal lesion in non-contiguous arterial segments. 
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 Definitions for Renal Artery Lesions: 
1. Severe renal artery stenosis (RAS) is >70% diameter stenosis by visual estimation, or 50% 
to 70% visually estimated stenosis with a mean resting or hyperemic translesional gradient 
of ≥ 10 mm Hg or a systolic resting or hyperemic translesional gradient of ≥ 20 mm Hg, or a 
renal fractional flow reserve (Pd/Pa) of ≤ 0.8 (Table 1).  Moderate RAS is 50% to 70% 
visually estimated stenosis without measurement of a translesional gradient, or with a 
resting or hyperemic translesional mean gradient < 10 mm Hg or a translesional systolic 
resting or hyperemic gradient of < 20 mm Hg.  
2. Resistant hypertension is uncontrolled hypertension (e.g. >140/90 mmHg) on three or 
more maximally tolerated antihypertensive medications including a diuretic. 
3. CKD class II is a GFR of 60-89 mL/min; CKD class III is GFR of 30 - 59 mL/min; CKD class IV 
is GFR < 30 mL/min. 
 
 Definitions for Aorto-Iliac Lesions: 
1. Focal aorto-iliac lesions are ≤ 4 cm in length.   
2. Diffuse aorto-iliac lesions are > 4 cm in length. 
 
 Definitions for Femoral-Popliteal Lesions: 
1. Focal femoral-popliteal lesions are ≤ 10 cm, intermediate are 10 - 20 cm, and diffuse are > 
20 cm. 
 
 Definitions for Infra-Popliteal Lesions: 
1. One-vessel infra-popliteal disease implies that two tibial arteries are without 
hemodynamically significant stenosis (≥70% or occlusion); Two-vessel infra-popliteal 
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disease implies that one tibial artery is without hemodynamically significant stenosis or 
occlusion (tibioperoneal trunk disease affects both the posterior tibial and peroneal arteries 
which is consistent with two-vessel infra-popliteal disease); Three-vessel infra-popliteal 
disease implies that all three tibial arteries have hemodynamically significant stenosis 
and/or occlusion. 
2. A focal infra-popliteal lesion is a discrete area of narrowing ≤ 4 cm long. An intermediate 
infra-popliteal lesion is a continuous segment of disease 4 to 10 cm long. A diffuse infra-
popliteal lesion is a continuous segment of disease > 10 cm long. 
 
Renal Interventional Updates (Table 2) 
 Introduction:  Renal hypoperfusion leads to the activation of the renin-angiotensin-
aldosterone axis.  This results in vasoconstriction, sodium and water retention, aldosterone 
secretion, and sympathetic nervous system activation1,7, which in turn can lead to systemic 
hypertension or cardiac destabilization syndromes (flash pulmonary edema, refractory heart 
failure and/or unstable angina). Renal hypoperfusion may also lead to ischemic nephropathy and 
chronic kidney disease (CKD).  There has been great interest in relieving renal hypoperfusion when 
it is secondary to atherosclerotic stenosis at the renal artery ostium and/or proximal aspect of the 
renal artery or arteries with stent deployment.8 Table 3 summarizes the most current ACC/AHA 
guidelines update on renal intervention.9 
 Several prospective, multicenter registries have demonstrated improvements in systolic 
and diastolic blood pressure (SBP, DBP) and improvement and/or stabilization of renal function for 
renal stent placement with excellent safety profiles, but have not shown any improvement in major 
adverse cardiovascular events.1,10-12  A large multicenter randomized controlled CORAL 
(Cardiovascular Outcomes in Renal Atherosclerotic Lesions) trial13 demonstrated that for patients 
with hypertension and newly diagnosed renal artery stenosis, the most appropriate therapy was to 
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maximize medical therapy before considering revascularization.  The CORAL study found that the 
primary composite end point (death from cardiovascular or renal causes, myocardial infarction, 
stroke, hospitalization for congestive heart failure, progressive renal insufficiency, or the need for 
renal replacement therapy) in patients with renal artery stenosis (>60% diameter stenosis) and 
hypertension did not differ between groups treated with GDMT alone compared to GDMT with 
renal stenting.14  
 The CORAL trial has limitations similar to other previous comparative renal artery stent 
trials.15,16 These include enrolling patients with moderate hypertension receiving only two 
antihypertensive medications, not requiring maximally tolerated doses, and the majority of 
enrolled patients having moderate (68% diameter stenosis) renal artery stenosis and without 
hemodyanmic confirmation of the severity of obstruction.  
 At baseline, CORAL participants were taking 2.1 ± 1.6 anti-hypertensive medications with a 
systolic blood pressure of 150 ± 23 mmHg. At the conclusion of the trial, both the medical therapy 
cohort and the group that underwent renal revascularization had increased the number of 
medications required, 3.5 ± 1.4 versus 3.3 ± 1.5, respectively (P=ns) and both groups had 
comparable decreases in systolic blood pressure, 15.6 ± 25.8 mm Hg in the medical therapy group 
and 16.6 ± 21.2 mm Hg in the stent group.  These findings indicate that relatively few patients with 
refractory hypertension were enrolled in the CORAL trial.   
 
 Anatomic Considerations: Expert consensus and experimental evidence have determined 
that a hemodynamically severe renal artery diameter stenosis is present when there exists a resting 
or hyperemic translesional mean pressure gradient of ≥10 mm Hg, a resting or hyperemic peak 
systolic translesional pressure gradient of ≥20 mm Hg or renal fractional flow reserve (FFR) ≤0.8 
(Table 1).17-20  The pressure gradient is best measured with an 0.014" pressure wire and not a 
catheter; even the use of a 4Fr catheter results in a 75% overestimation of the translesional systolic 
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pressure gradient.21  Moreover, patients with global renal ischemia (i.e. those with bilateral, 
hemodynamically significant RAS or those with unilateral RAS with a solitary functioning kidney) 
are thought to be more likely to respond to renal artery stent placement. 
 
 Clinical Considerations: Several meta-analyses22,23 have shown that fewer anti-
hypertensive medications are required to achieve desired blood pressure reduction following renal 
artery revascularization. Future trials may yield the most robust insights into the value of renal 
artery stenting if: they only enroll patients with hemodynamically-significant lesions, as 
determined by invasive measurement in a controlled, standardized fashion; if they include an 
assessment of anti-hypertensive medication compliance; and if they are based on accurate blood 
pressure assessment, including ambulatory 24 hour blood pressure monitoring. 
 It is difficult to demonstrate the cost-effectiveness of renal artery stenting without 
unequivocal clinical benefit in the populations studied.  The few available cost-effectiveness 
analyses hav  predated publication of most randomized controlled trials.  Nevertheless, a German 
economic analysis of hypertensive patients with renal artery stenosis used a decision analytic 
model to predict 3-year costs.24  They observed a cost benefit of €11,663 ($13,044), €36,454 
($40,771), €51,752 ($57,881) and €78,766 ($88,095), for stenting, surgery, PTA and medical 
therapy, respectively, and concluded that a strategy of primary renal stenting was the most cost-
effective strategy in this setting. 
 
 Technical Considerations: The increasing adoption of transradial arterial access for 
coronary and peripheral vascular intervention has inspired significant interest into the application 
of this approach for renal artery stenting. Since most renal arteries have a natural downward 
angulation, they may often be easier to engage with a catheter advanced from a superior approach 
(i.e. the arm) compared with a catheter directed from the femoral approach. The availability of 125 
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cm guiding catheters and balloons and stents with longer shafts (e.g. 150 cm) make renal artery 
stenting from the transradial approach feasible for most patients.   
 
Aorto-Iliac Interventional Updates (Table 4) 
 Introduction: The goals of therapy for patients with aorto-iliac atherosclerotic disease have 
not changed. The key objectives are to reduce or alleviate the symptoms associated with vascular 
insufficiency, to improve functional status and quality of life (QOL), and to reduce cardiovascular 
morbidity and mortality with GDMT, supervised exercise therapy, and in selected patients, 
revascularization.  There are additional indications for aorto-iliac endovascular therapy in patients 
who do not experience symptoms of lower extremity arterial insufficiency; these include situations 
where large-bore arterial access is required for hemodynamic support devices (e.g. intra-aortic 
balloon pumps (IABP) or other catheter-based ventricular assist devices), for structural, valvular  
(e.g. TAVR), and vascular (e.g. endovascular aortic aneurysm repair (EVAR)) procedures. 
Since the publication of the SCAI Aorto-Iliac AUC document2, two trials have been 
completed evaluating the impact of supervised exercise therapy (SET) and EVT for aorto-iliac 
arterial disease. The Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial 
was a randomized clinical trial (RCT) that compared EVT, optimal medical therapy (OMT) and SET. 
At 18 months, the peak-walking time improved for both SET and EVT and was not different 
between the two groups. Improvement in claudication onset time was greater for SET compared 
with OMC, but not for EVT compared with OMC. Many disease-specific quality-of-life scales 
demonstrated durable improvements that were greater for EVT compared with SET or OMC. In 
summary, the CLEVER trial demonstrated an improvement in QOL and peak walking time with EVT 
or with SET when compared to OMT alone after 18 months of follow-up (Figure 1).   
The CLEVER investigators conducted a 5-year cost-effectiveness analysis using the 18-
month follow up data.25  Assuming that the quality of life benefits associated with each treatment 
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strategy would dissipate over time, they calculated incremental cost-effectiveness ratios of $24,070 
and $41,376 per quality adjusted life year gained for supervised exercise and stenting, respectively, 
when compared with optimal medical therapy alone.  They concluded that supervised exercise and 
stenting were both economically attractive by US standards. 
The Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease 
and Intermittent Claudication (ERASE) trial 26 randomized patients with claudication due to aorto-
iliac and femoral-popliteal arterial disease to receive EVT together with SET or to receive SET alone.  
The ERASE trial demonstrated that those who received both EVT and SET had greater improvement 
in walking distance and health-related QOL compared with those who received SET alone.  These 
trials support SET as an effective alternative to revascularization, but indicate that combining SET 
with EVT, in the presence of GDMT, may represent the best option overall. The ERASE trial suggests 
that combination therapy of EVT with SET should be considered in suitable patients given the 
marked gains in QOL and walking distance. 
 The updated ACC/AHA Peripheral Artery Disease guidelines27 continue to support EVT, 
with primary or provisional stenting, as first-line therapy for symptomatic aorto-iliac occlusive 
disease states that "Endovascular procedures are effective as a revascularization option for patients 
with lifestyle limiting claudication and hemodynamically significant aorto-iliac occlusive disease“.  
Due to its high success rates and lower morbidity/mortality compared to surgical revascularization, 
EVT, with primary or provisional stenting may be considered a first-line treatment strategy for 
aorto-iliac disease. 28-31 
 
 Anatomic Considerations: The TASC-II document32, recently updated33, has traditionally 
been used to describe the anatomic characteristics of lower extremity atherosclerotic disease as 
they relate to therapeutic options (Figure 2). The initial writing group had a preference for surgical 
intervention in more anatomically complex lesions (TASC C/D). Over the decade since the 
Page 12 of 56
Catheterization and Cardiovascular Interventions
Catheterization and Cardiovascular Interventions
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
For Review Only
PAD Appropriate Use Criteria 
 13
document’s publication, however, advances in technology and operator technique now permit safe, 
effective, and relatively durable treatment of even the most complex (TASC C/D) lesions with EVT.33 
A recent large retrospective study from Japan34 demonstrated that in a cohort of 2,096 patients 
with complex aorto-iliac disease, of which 395 had TASC D lesions (remaining 2,206 patients were 
TASC A-C), there was no difference in the 5 year primary patency (77.9% vs. 77.1%, P = 0.17) or 
major adverse cardiovascular and limb events (30.5% vs. 33.4%, P = 0.42) between the less 
complex lesions (TASC A-C) and the more complex lesions (TASC D).  The study did confirm the 
technical challenges associated with EVT in complex lesion subsets, yielding a lower procedural 
success rate (91.6% vs. 99.3%, P < 0.01) and a greater rate of procedure-related complications 
(11.1% vs. 5.2%, P < 0.01) in the TASC D group when compared to the TASC A-C lesion cohort.  
The STents versus AnGioplasty (STAG)35 trial randomized primary stenting against PTA for 
iliac occlusion and was stopped early due to a high rate of embolic complications in the PTA 
treatment group. Primary stenting improved technical success and lowered major procedural 
complication rates, but there was no statistical difference for patency after 1 and 2 years. 
The BRAVISSIMO36 (Belgiane Italian tRial investigating Abbott Vascular Iliac StentS In the 
treatMent of TASC A, B, C, & D iliac lesiOns) study was a prospective multicenter registry treating 
325 patients with aorto-iliac lesions.  The technical success was 100%, which reflects advances in 
operator techniques and device technology including re-entry catheters, crossing devices, and stent 
design. The overall 24-month primary patency rate was 87.9% (88.0% for TASC A, 88.5% for TASC 
B, 91.9% for TASC C, and 84.8% for TASC D (P = not significant)). Neither TASC category nor lesion 
length was predictive of restenosis, providing further support for an “endovascular first” strategy 
regardless of TASC classification. 
Regardless of stent selection, operators must recognize the pretreatment risk factors 
predictive of late restenosis/occlusion which include: occlusion versus stenosis, longer lesions, 
external iliac over common iliac lesion location, and smaller arteries especially those with 
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circumferential calcification.37 The long-term patency of endovascular intervention of the aorto-
iliac arteries may differ by gender with lower patency rates in women, although this finding may 
reflect smaller vessel diameter. 38  
 
 Clinical Considerations: Since 2014, there has been a marked increase in the use of TAVR 
via the transfemoral approach. Computed tomographic angiography (CTA) is routinely used to size 
the aorto-iliac arteries and to identify potential impediments to transfemoral valve delivery. 
Physicians with the endovascular skills necessary to repair aorto-iliac and femoral arterial trauma 
secondary to large caliber trans-femoral devices (e.g. used for structural, valvular, or hemodynamic 
support), should be available to avoid or minimize potentially catastrophic complications.  TAVR 
teams should have immediate access to large diameter balloons and covered stents in case of aorto-
iliac rupture or perforation. Current appropriate use criteria support endovascular intervention for 
asymptomatic aorto-iliac arterial disease to allow vascular access for life-saving devices (e.g., 
mechanical circulatory support, or TAVR).  This can be accomplished with primary or provisional 
stent placement. 2  
Internal iliac artery intervention is effective in patients with lifestyle limiting buttock or hip 
claudication due to stenotic disease.  Internal iliac revascularization may be appropriate when there 
is a significant stenosis and vasculogenic impotence, although the current guidelines do not address 
the treatment of vasculogenic impotence and the data supporting revascularization are limited to 
small single enter studies.39  
 
 Technical Considerations: Both nitinol and stainless steel self-expanding stents perform 
well in the iliac location with low restenosis rates.40-44  A recent multicenter trial randomized 660 
patients with Rutherford Classification (RC) 1 - 4 to treatment with either a balloon expandable 
(BE) or self-expanding (SE) stent.  The primary patency at 12 months favored the SE over BE with 
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an SE restenosis rate of 6.1% and 14.9% after BE (P=0.006).45 Usually, balloon-expandable stents 
are chosen for ostial lesions where precise placement is a priority, or when significant recoil is 
anticipated, while self-expanding stents more readily contour to tapering and tortuous vessels.  
While drug-eluting stents (DES) and drug coated balloons (DCB) have not been evaluated in iliac 
arteries, in highly selected cases, they may be useful in an appropriately sized vessel with in-stent 
restenosis.46   
The overall results for TASC B, C, and D lesions in the COBEST (COvered versus Balloon 
Expandable Stent Trial) trial47 did not find any differences for binary restenosis or freedom from 
occlusion at 18 months between the covered and non-covered balloon expandable stents.  
However, the more complex TASC C and D lesion cohort of that trial did have an improved primary 
patency rate when covered balloon-expandable stents were used as compared to bare metal stents 
(BMS).  The recently published 5-year data from this trial continue to demonstrate an advantage for 
covered versus BMS in TASC C and D iliac artery lesions.48  A recent meta-analysis of RCTs and 
observational studies found that covered stents in iliac arteries were not associated with a 
significant improvement in primary patency, but were associated with a higher ankle-brachial 
index and a lower reintervention rate.49 
 There has been rapid adoption of transradial access for coronary angiography and 
interventions. There is growing interest in the transradial approach for renal, mesenteric and lower 
extremity intervention in suitable patients. 50,51   Pre-procedural planning is required to ensure that 
large diameter balloons and stents on shaft lengths of at least 150 mm may be delivered through 
radial access arterial sheaths (4-7 French).52  
An essential aspect of appropriate care is the determination of the clinical and 
hemodynamic significance of aorto-iliac lesions. Given the limitations of two-dimensional 
angiography, physicians should consider assessing the severity of moderate (50% to 70% diameter 
stenosis) lesions by measuring translesional gradients using microcatheters or pressure wires.  A 
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translesional mean gradient of ≥ 10 mmHg, at rest or with hyperemia, is considered significant in 
this vascular bed given the size of these vessels and the peak flow that occurs with exercise. 53,54  
 
Femoral-Popliteal Interventional Updates (Table 5) 
Introduction:  The goals of endovascular therapy for patients with PAD are driven by the 
severity of the patient’s clinical condition, and by the anatomic features and distribution of the 
vascular disease. The clinical objective in treating a patient who is functionally impaired due to 
claudication is the relief of symptoms with as durable a treatment as possible.  Endovascular 
therapy, no matter how expertly performed, may be hampered by restenosis and the recurrence of 
symptoms.   
In the patient presenting with CLI, with threatened limb or tissue loss, the objective is to 
restore perfusion of the ischemic tissue as rapidly as possible, in order to relieve the ischemia, 
prevent or limit the amount of tissue loss, and restore ambulation.  In treating patients with CLI, 
durable patency remains desirable; but once the wound has healed, restenosis may not place the 
limb in jeopardy unless re-injury occurs.  
Several trials have shown significant patient benefit with OMT and SET therapy in relieving 
symptoms of claudication at one year. 55-57  In 2014, the IRONIC 58(Invasive Revascularization or 
Not in Intermittent Claudication) trial which randomized patients with both aorto-iliac and 
femoral-popliteal disease to revascularization (endovascular or surgical, n=79) plus OMT or to OMT 
alone (n=79) demonstrated superiority for EVT plus OMT for onset of claudication and quality of 
life (QOL) outcomes compared to group treated with OMT alone (P=0.003).  
A recent meta-analysis59 of over 7,000 patients of SET vs. OMT vs. EVT showed that only 
SET increased median walking distance, although both EVT and SET improved QOL scores 
compared to OMT alone.  Another meta-analysis compared the four different approaches to treating 
with PAD and claudication, i.e. surgery, EVT, SET and OMT alone.  In this review of 1,548 patients60, 
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the authors found that surgery, EVT and SET were superior to OMT with respect to walking 
distance, and claudication.  Another comparative effectiveness study examined the utility of EVT for 
femoral-popliteal disease causing claudication and also confirmed improved walking parameters 
and QOL.60-62 
 
Anatomic Considerations: The 2007 TASC II document recommended surgical 
intervention for more complex femoral-popliteal lesions (TASC C/D) with EVT reserved for less 
complex TASC A and B lesions.  The 2015, TASC update endorses an "endovascular first" 
recommendation for experienced operators and teams (Figure 3).33  With advances in technique 
and technology including strategies to approach complex chronic total occlusions with re-entry 
techniques and crossing devices , complex TASC D lesions are often approached with EVT first.  The 
most recent ACC/AHA guidelines on PAD provide a class IIA recommendation (Level of Evidence 
(LOE) B) for EVT. 27   These recommendations emphasize that the benefit of EVT in claudicants is 
related to durable patency, which is influenced by numerous patient and lesion specific 
characteristics. Given the smaller vessel diameter, longer lesion length, association of dense 
calcification and complex biophysical forces63, the femoral-popliteal arteries have lower long-term 
patency rates compared to the iliac arteries.  The recently updated ACC/AHA guidelines and the 
updated TransAtlantic Inter-Society Consensus (TASC II) supplement recommend an endovascular-
first approach when possible and that  “the choice of endovascular therapy as a revascularization 
approach for claudication due to femoral-popliteal disease should include a discussion of outcomes, 
addressing the risk of restenosis and repeat intervention, particularly for lesions with a poor 
likelihood of long-term durability”.27,33   
Common femoral endarterectomy (CFE) has been the gold standard for the treatment of 
common femoral arterial (CFA) disease based upon single center series and expert consensus.64  
However, a recent report from a large national database (American College of Surgeons: National 
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Surgical Quality Improvement Program [ACS-NSQIP]) on 1,843 patients undergoing CFE found an 
overall 15% risk of combined mortality/morbidity (3.4% mortality, 8% wound-related 
complications, 10% surgical take-backs).65  They concluded that CFE was not as "benign" a 
procedure as has been previously believed.   
Recently published evidence supports an endovascular-first approach to CFA disease with 
registry data reporting mortality/morbidity rates of ≤ 7.2%. 66  Long-term, 5-year follow-up of CFA 
stenting demonstrates a very favorable freedom from target lesion revascularization (TLR) of 79%. 
The Endovascular Versus Open Repair of the Common Femoral Artery (TECCO)” trial 
(ClinicalTrials.gov identifier NST01353651) randomized 117 patients comparing CFE to EVT for 
isolated CFA lesions. 67 The primary outcome, the morbidity and mortality rate within 30 days, 
occurred in 16 of 61 patients (26%) in the CFE group and 7 of 56 patients (12.5%) in the EVT group 
(odds ratio, 2.5; 95% CI, 0.9 to 6.6; P=0.05). The mean duration of hospitalization was significantly 
lower in the EVT group (3.2 ± 2.9 days versus 6.3 ± 3 days; p<0.0001). At 24-months, the sustained 
clinical improvement, the primary patency rate, and the target lesion and extremity 
revascularization rates were not different in the two groups. This trial demonstrates that for de-
novo CFA lesions, EVT can achieve comparable two-year patency rates with CFE and offer 
significantly lower 30 day morbidity and mortality rates. 
 
Clinical Considerations: Clinically relevant femoral-popliteal disease is defined as a ≥70% 
diameter stenosis. Moderate lesions are defined as 50%–69%, and mild lesions consist of <50% 
diameter stenosis. The severity and clinical impact of a lesion is also affected by its length, reference 
vessel diameter, arterial calcification, and quantity of atherosclerotic plaque (plaque burden). At 
this time, there are no published data regarding the use of translesional pressure gradients to 
assess the severity of femoral-popliteal PAD. 3 
An economic analysis was performed based upon National Institute for Health and Care 
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Excellence (NICE) guideline-recommended treatment of symptomatic femoral-popliteal artery 
disease with PTA and bailout BMS versus primary BMS placement, or DCB, or DES treatment.  Over 
a 24 month period, the benchmark TLR for de novo lesions with PTA of 36.2% was reduced to 
17.6% by DCB at a cost of £43 ($65), to 19.4% by DES at a cost of £44 ($67) and to 26.9% by BMS at 
a cost of £112 ($170).  There was a cost-effective benefit for quality-adjusted of life year, with a 
small cost reduction in the price of DCB and DES making drug-eluting therapy preferable.68  A cost-
effectiveness analysis of the IN.PACT SFA II (IN.PACT Admiral Drug-Coated Balloon vs. Standard 
Balloon Angioplasty for the Treatment of Superficial Femoral Artery [SFA] and Proximal Popliteal 
Artery [PPA])  trial compared the DCB (IN.PACT Admiral DCB (Medtronic, Santa Rosa, California)  
used in the trial to standard PTA.69  They concluded that for patients with femoral-popliteal disease, 
DCB angioplasty is associated with better 2-year outcomes and similar target limb–related costs 
compared with standard PTA.  A formal cost-effectiveness analysis suggests that use of the DCB 
angioplasty is likely to be economically attract ve.  An important caveat is that the efficacy of DCB 
and DES, may not represent a "class effect", but that the dose of drug and/or excipient used to bind 
the drug may make uniquely affect each device's cost-effectiveness profile unique.70  
 
Technical Considerations: There have been significant technological advances and further 
development of the evidence base for the treatment of femoral-popliteal arterial lesions since the 
original SCAI appropriate use document was published. 3,71  I  
Drug-Coated Balloons (DCB):  There have been several clinical trials involving DCBs in 
femoral-popliteal arteries since the 2014 SCAI AUC publication.  Several RCTs involving the use of 
drug-coated balloons (DCB) have demonstrated significant improvement in vessel patency rates 
compared with PTA alone. 72-75 The IN.PACT SFA (Randomized Trial of IN.PACT Admiral Drug 
Eluting Balloon vs. Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease) 
trial72 randomized a paclitaxel DCB (Medtronic, Santa Clara, CA) to an uncoated PTA balloon in 
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patients with femoral-popliteal PAD (mean lesion length of 8.94 ± 4.89 cm).  Total occlusions were 
present in 25.8% of the DCB and 19.5% of the PTA groups (P=0.22).  The DCB group had higher 
primary patency (82.2% vs. 52.4%; P<0.001) at 12 months and a very low rate of clinically driven 
TLR (2.4% in the DCB arm vs. 20.6% in the PTA arm; P<0.001).   These benefits persisted at 24 
months with higher primary patency (78.9% vs. 50.1%; P < 0.001) and lower rates of clinically 
driven TLR were 9.1% and 28.3% (P < 0.001).76 A formal analysis based on the two-year results 
suggests a 70% to 80% likelihood that the DCB is an economically attractive strategy.69   
Additional evidence supporting the use of DCBs in the femoral-popliteal segment comes 
from the LEVANT (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal 
Restenosis) I and II trials, which used a different, lower-dose, paclitaxel DCB (Lutonix, Bard, Tempe, 
AZ).  Both LEVANT studies confirmed the safety profile of this DCB and demonstrated improved 
patency at 12 months compared to PTA alone (65.2% vs. 52.6%; P=0.02). The proportion of 
patients free from primary safety events was 83.9% with the DCB and 79.0% with uncoated PTA (P 
= 0.005 for non-inferiority).   
The THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal 
Arteries) trial77 also investigated the treatment of femoral-popliteal arteries with a paclitaxel-
coated balloon and recently reported the 5-year results.78  At 5 years, the TLR rate (21% vs. 56%; P 
= 0.0005) favored DCB treatment versus PTA alone with no signs of drug-related local vessel 
abnormalities. 
The use of DCBs prior to bare metal stenting also has been evaluated in the Drug Eluting 
Balloon in Peripheral Intervention for the Superficial Femoral Artery (DEBATE-SFA) trial79 which 
randomized the use of a paclitaxel DCB vs. PTA for femoral-popliteal disease.   In both groups, 
bailout stenting was performed with bare metal stents (BMS). In 104 patients (110 lesions) with a 
mean lesion length for DCB of 94±60 vs. 96±69 mm for PTA, the primary endpoint (one-year 
restenosis) was lower in the DCB group (17% vs. 47.3%); P = 0.008). Registry data supports the 
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effectiveness of DCBs in long femoral-popliteal disease (> 15 cm) reporting that 105 consecutive 
patients with RC 2 to 4 and a treated lesion length of 25 ± 7 cm obtained a one-year patency rate of 
83.2% with only 11% requiring bailout stents. 80  
Drug-eluting stents (DES): The Zilver PTX DES (Cook Medical, Bloomington, IN) continues to 
show promise with data from real-world registries81 and 5-year data from the randomized Zilver 
PTX trial also demonstrated continued safety and clinical durability in comparison with PTA.82 This 
trial had a 2-stage randomization with initial randomization to DES (n=236) or PTA (n=238). 
Patients who were initially randomized to PTA (n=238) and experienced flow-limiting dissections 
and/or recoil requiring stenting then were secondarily randomized to provisional BMS (n=59) or 
DES (n=61).  The remaining 118 patients (not randomized to DES or BMS) were in the standard 
care group.  At 5 years, DES showed a significant clinical benefit compared to PTA alone for freedom 
from persistent or worsening symptoms of ischemia (79.8% versus 59.3%, P < 0.01), patency 
(66.4% versus 43.4%, P < 0.01), and freedom from TLR (83.1% versus 67.6%, P < 0.01). In patients 
who did und rgo a second randomization to either DES or BMS, there was a sustained benefit of 
DES.  At 5 years, the provisional DES recipients when compared to the BMS group had improved 
clinical benefit (81.8% versus 63.8%, P=0.02), patency (72.4% versus 53.0%, P=0.03), and freedom 
from TLR (84.9% versus 71.6%, P=0.06). These results represent a >40% relative risk reduction in 
restenosis and TLR through 5 years for the overall DES in comparison with standard care and for 
provisional DES in comparison with provisional BMS.  The cost-effectiveness of DES for the 
treatment of femoral-popliteal PAD remains to be rigorously studied.  
Covered Stents: Two randomized controlled trials, VIASTAR83 (VIABAHN Endoprosthesis 
with Propaten Bioactive Surface versus Bare Nitinol Stent in the Treatment of Long Lesions in 
Superficial Femoral Artery Occlusive Disease) and VIBRANT84 (VIABAHN Endoprosthesis versus 
Bare Nitinol Stent in the Treatment of Long Lesion (≥ 8 cm) Superficial Femoral Artery Occlusive 
Disease) have demonstrated an inconsistent patency advantage for covered stents compared to 
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self-expanding BMS in the femoral-popliteal territory.   
The one-year patency in the VIASTAR group was 70.8% by intention to treat with no 
statistical advantage over the BMS group (55.1%, P = 0.11), but when analyzed by treatment 
received, the covered stent’s 1-year patency was 78.1%, which was superior to BMS (53.5%, P = 
0.009). 83   The patency rates for the covered stent fell considerably at two years (63.1%)85 and even 
further at three years (24.2%).84 
Non-Stent Options:  There is no comparative evidence supporting directional, rotational or 
orbital atherectomy as a superior treatment to PTA alone in de-novo femoral-popliteal lesions. All 
studies to date involving these modalities have been registries and subject to limitations and bias 
inherent to single arm registries.  In addition, debulking tools such as atherectomy and LASER carry 
a risk of distal embolization. Embolic protection devices are often used to decrease this potential 
complication. Additionally, operator experience and meticulous attention to technique is required 
with each of these devices to ensure the safety of the procedure.  In the DEFINITIVE LE 
(Determination of EFfectiveness of the SilverHawk_ PerIpheral Plaque ExcisioN System 
(SIlverHawk Device) for the Treatment of Infrainguinal VEssels / Lower Extremities) registry, distal 
embolization occurred in 3.8% and arterial perforation occurred in 5.3% of cases.86  A recent single-
center study of femoral-popliteal patients undergoing directional atherectomy with the routine use 
of distal embolic protection demonstrated presence of macroemboli in 62% of patients.87 
The treatment of femoral-popliteal in-stent restenosis (ISR) is exceptionally challenging due 
to high rates of reoccurrence.  The Femoral Artery In-Stent Restenosis (FAIR) trial88 randomized 
119 patients with femoral-popliteal ISR to either DCB (n=62) or PTA (n=57).  These lesions were 
short to intermediate in length (mean lesion length was 82.2±68.4 mm) with nearly 30% being 
occlusions and another 25% with moderate to severe vessel calcification. Based on duplex 
ultrasonography the primary end point of recurrent in-stent restenosis was 15.4% (8 of 52) in the 
DCB and 44.7% (21 of 47) in the PTA group (P = 0.002) at 6 months.  DCB treated vessels had a 
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greater freedom from TLR (DCB 96.4% vs. 81.0% ; P =0.012) at 6 months and at 12 months (90.8% 
vs. 52.6%; P <0.0001).  Clinical improvement, an improvement in Rutherford class by ≥ 1 without 
the need for TLR, was observed in 78% of the DCB patients vs. 52% of the PTA patients (P = 0.015) 
at one year. 
For those patients presenting with ISR, several studies suggest that an initial strategy 
focused on debulking of the restenotic tissue may be helpful.  LASER atherectomy was evaluated in 
two studies for the treatment of ISR, resulting in an FDA-approved indication for ISR. The Excimer 
LASER Randomized Controlled Study for Treatment of Femoropopliteal In-Stent Restenosis 
(EXCITE-ISR) trial89 was a randomized controlled study of excimer LASER atherectomy (ELA) plus 
PTA versus PTA alone for femoral-popliteal ISR in 250 patients. The study was stopped early 
secondary to early efficacy demonstrated at the interim analysis. A total of 169 ELA plus PTA 
patients (62.7% male; mean age 68.5 ± 9.8 yr) and 81 PTA patients (61.7% male; mean age 67.8 ± 
10.3 yr) were enrolled with a mean lesion length of 19.6±12.0 cm vs. 19.3±11.9 cm, respectively.  
One third of patients had chronic total occlusions.  Those patients treated with ELA plus PTA 
demonstrated superior procedural success (93.5% vs. 82.7%; p=0.01) with significantly fewer 
procedural complications. Six-month freedom from TLR was 73.5% (ELA-PTA) vs. 51.8% (PTA)  
(p<0.005), and 30-day major adverse event rates were 5.8% vs. 20.5% (p<0.001), respectively. 
Overall, ELA+PTA was associated with a 52% reduction in TLR for the treatment of femoral-
popliteal ISR.  
Another trial90 of ELA for the treatment of ISR involved CLI patients with occlusion of the 
femoral-popliteal segment secondary to ISR. These 48 patients were randomized to DCB vs. 
ELA+DCB. The results suggest that debulking of the ISR tissue prior to the use of DCB was beneficial 
in this challenging patient population.  In the ELA + DCB group, the patency rates at 6 and 12 
months (91.7% and 66.7%,) were significantly higher (p=0.01) than in the DCB only patients 
(58.3% and 37.5%, respectively). TLR at 12 months was 16.7% in the ELA + DEB group and 50% in 
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the DEB only group (p=0.01).   
 
Infra-Popliteal Interventional Update (Table 6) 
Introduction:  Revascularization of infra-popliteal PAD is generally limited to those 
patients presenting with critical limb ischemia (CLI) where in-line flow to the foot is the standard of 
care for wound healing and/or resolution of rest pain. 91  In general, non-ambulatory patients with 
a shortened life expectancy and extensive lower extremity tissue necrosis should undergo primary 
amputation at the lowest level possible to ensure healing of the surgical site.  Patients who have the 
opportunity to regain ambulatory function should undergo non-invasive testing with an ankle-
brachial index (ABI), toe-brachial index (TBI), or other modalities such as TcPO2 or skin perfusion 
pressure. However, the ABI ,may be normal or non-compressible in approximately 30% of patients 
with isolated infrageniculate disease. 92,93  In these individuals,  non-invasive modalities such as 
magnetic resonance angiography (MRA) or computed tomographic angiography (CTA) may be 
necessary.  However, in most cases digital subtraction angiography (DSA) is the gold standard to 
visualize the extent of lower extremity arterial disease including foot and pedal arch. 27 
 
Anatomic Considerations: Patients with CLI typically have disease involving multiple 
levels (i.e., aorto-iliac, femoral-popliteal and infra-popliteal), but less than 10% of patients with CLI 
have hemodynamically significant disease at all three levels.  The updated 2015 TASC document 
includes, for the first time, an anatomic classification for infra-popliteal atherosclerotic disease 
(Figure 4).33  Infrainguinal PAD can be further subdivided into those with predominantly isolated 
infra-popliteal disease (~33%) and those with both femoral-popliteal and infra-popliteal disease 
(~67%).94-97  Isolated infra-popliteal disease is mainly seen in the elderly (>80 years old), diabetic, 
or patients with advanced stages of chronic kidney disease.95 This arterial bed consists of relatively 
small caliber arteries, which are often calcified and associated with diffuse, multi-segment disease.4  
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These patients are at higher risk for amputation and have a shorter amputation-free survival (AFS) 
compared to those with combined femoral-popliteal and infra-popliteal disease.96 Prior to 
considering infra-popliteal intervention, all hemodynamically significant inflow disease should be 
treated to normalize inflow to the infra-popliteal circulation. Then, if deemed clinically necessary, 
one may proceed with revascularization of the infra-popliteal disease.  
However, even if major amputations are avoided, complete wound healing may be elusive 
with inframalleolar disease.  Recent evidence shows that delayed, and/or incomplete wound 
healing adversely affects quality of life and social rehabilitation. Several trials have also 
demonstrated the negative influence of inframalleolar disease on wound healing rates.98 99  
 
Clinical Considerations: Patients with infra-popliteal disease and claudication should be 
preferentially treated with cilostazol (if a candidate), a supervised exercise program, and 
guidelines-based anti-atherosclerotic medical therapy, before considering a revascularization 
procedure. The most recent ACC/AHA guidelines emphasize this with a class IIb level of evidence 
(LOE) C (limited data (LD)) stating that “The usefulness of endovascular procedures as a 
revascularization option for patients with claudication due to isolated infra-popliteal artery disease 
is unknown”.27  
Infra-popliteal EVT is generally reserved for patients with CLI. For patients with 
claudication, only moderate to severe (≥50% diameter stenosis) lesions and multivessel tibial 
disease (≥ 2 tibial vessels) should be considered for revascularization.  The goals of therapy for CLI 
patients (Rutherford 4–6) with infra-popliteal arterial disease include: relieving pain, healing 
ulcerations, preventing major amputation, improving the patient’s QOL, and prolonging survival.4 
Angiographically, severe infra-popliteal stenosis is defined as a luminal diameter stenosis of ≥70% 
in at least one infra-popliteal artery.96,100,101 Moderate stenosis is defined as a luminal reduction of 
50–69% and mild stenosis is defined as a luminal reduction of <50%. Obstructive disease in the 
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below-knee popliteal artery limits blood flow to the three tibial vessels (anterior, posterior and 
peroneal) and is equivalent to three vessel disease, while narrowing of the tibioperoneal trunk 
affects two tibial arteries (peroneal and posterior tibial) and is equivalent to two-vessel disease.  
A focal infra-popliteal lesion is a discrete area of narrowing ≤ 4 cm long. An intermediate infra-
popliteal lesion is a continuous segment of disease >4 to 10 cm long. A diffuse infra-popliteal lesion 
is a continuous segment of disease >10 cm long..64  
Infra-popliteal intervention procedural success is commonly defined as the re-
establishment of direct “in-line” pulsatile flow to the foot.  It is currently unknown whether healing 
rates are improved when in-line flow to the foot is established through more than one artery, but 
maximizing blood flow through more than one artery is particularly attractive in patients with 
inadequate collateral circulation, disease of the plantar arch vessels, or limb-threatening ischemia.4  
An angiosome is a vascular territory supplied by a specific source artery and was a principle 
originating from the plastic surgery literature.  This concept is based on areas of the foot 
(angiosomes) identified by injection of dye into cadaveric lower limbs without arterial insufficiency 
and therefore does not take into consideration any collateral circulation which is often present in 
CLI patients.  There remains uncertainty regarding the value of angiosome-guided revascularization 
with some studies finding no correlation between the angiosome-directed concept and lower limb 
revascularization outcomes.102-104 and other studies showing improved healing rates when 
compared to revascularization of the non-angiosome territory, particularly if there is poor pedal 
arch collateralization.99,105-107  In a small retrospective report, direct revascularization (angiosome 
based) versus indirect revascularization with good collateral circulation had similar outcomes 
whereas, indirect revascularization with poor collateral circulation fared the worst.108  However, 
realistically the angiosome-based revascularization strategy may be limited by the length and/or 
complexity of underlying disease, the extent of collateralization, and the anatomic variability among 
patients, including anatomic anomalies.95  
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The cost-effectiveness of infra-popliteal intervention is difficult to ascertain without robust 
randomized data.  Using a Markov simulation model, Barshes and colleagues examined various 
treatment strategies for patients with CLI and compared these to wound care plus amputation as 
needed.109  They determined that endovascular intervention and surgical bypass with endovascular 
revision as needed were more effective and less costly than wound care with or without 
amputation as long as the initial wound healing rates were ~50% and ~70%, respectively.  The 
relative cost-effectiveness of an endovascular or surgical-first strategy is being determined in the 
ongoing BEST-CLI trial.110 
 
Technical Considerations:  When focal disease of the infra-popliteal arteries required 
intervention, stenting with a coronary balloon expandable BMS stents was the primary 
revascularization strategy.111 PTA with bail-out stenting for an unsatisfactory PTA result with a self-
expanding stent, has been compared to primary stenting with a self-expanding BMS in the EXPAND 
(Primary Self-EXPANDing Nitinol Stenting vs Balloon Angioplasty With Optional Bailout Stenting 
for the Treatment of Infra-popliteal Artery Disease in Patients With Severe Intermittent 
Claudication or Critical Limb Ischemia) study.112  Ninety-two patients with infra-popliteal PAD and 
severe claudication or CLI were randomized 1:1 to either primary or provisional stenting with a 
self-expanding nitinol stent (Astron Pulsar/Pulsar-18 nitinol stent, Biotronik, Lake Oswego, OR)).   
There was no difference in clinical improvement (74.3% versus 68.6%, freedom from TLR (76.6% 
and 77.6%), mortality (7.4% versus 2.1%), or amputation [8.9% (major 6.7%) versus 13.2% (major 
8.7%) all (P>0.05)] at one year for primary versus provisional stenting with a self-expanding BMS.  
Drug-Eluting Stents (DES): There have been five randomized trials113-118 and several meta-
analyses 119-123 analyzing outcomes of infra-popliteal DES versus either PTA, BMS, or DCB.  The 
ACHILLES124 (Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infra-
popliteal Arterial Disease) trial randomized 200 patients with infra-popliteal disease to PTA or DES 
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(Cypher Select Sirolimus Eluting Stent, Cordis, Bridgewater, NJ, USA) and found superior patency 
rates at 1 year for the DES group (DES 75% versus PTA 57.1%, P = 0.025).  At 6 months, there was 
better wound healing with DES versus PTA (95% healing versus 60% healing, P = 0.048), but at 1 
year, the rates of complete wound closure with DES versus PTA (72.9% versus 55.6%; p = 0.088, 
respectively) were not different.  The QOL score improved significantly up to 1 year in the DES 
cohort (P < 0.0001), but not with the PTA group. There was a trend of more QALYs gained with DES 
compared with PTA up to 1 year after randomization.  For patients with total lesion lengths < 120 
mm, the 1-year restenosis rate for DES over PTA were 22.4% versus 41.9%, (P = 0.019) a difference 
that was even larger for diabetics (DES: 17.6% versus PTA: 53.2%, P < 0.001) who constitute the 
majority of patients with peripheral infra-popliteal disease.  There was no difference between the 
PTA or DES groups for death, amputation rates, or improved functional status.   
The DESTINY100 (Drug-Eluting Stents in the Critically Ischemic Lower Leg) study 
randomized 140 de novo CLI patients (RC 4,5) with infra-popliteal disease comparing BMS (Multi-
LinkVision, Abbott Laboratories, Abbott Park, IL, USA) to DES (Xience V, Abbott Laboratories, 
Abbott Park, IL, USA). Over 12 months of follow up, there was no difference for the percentage of 
patients with good functional outcomes (RC 0-1) between DES (60%) and BMS (56%) at 1 year, and 
there were very few amputations.  DES had superior patency (DES 85% versus BMS 54%, P = 
0.0001) and freedom from TLR (DES 91% versus BMS 66%, p=0.001). 113  
The YUKON-BTX (YUKON-Drug-Eluting Stent Below the Knee) trial125 randomized 161 
patients with severe claudication and CLI to infra-popliteal treatment with BMS or DES (Sirolimus 
eluting YUKON stent, Translumina, Hechingen, Germany)125.  Primary patency at 1 year for the DES 
group was 80.6% versus 55.6% with BMS (P = 0.004). At three years of follow-up there was 
significant clinical benefit for the DES group for event-free survival (DES 65.8% versus 44.6% for 
BMS, P = 0.02), reduced amputation rates (DES 2.6% versus BMS 12.2%, P = 0.03) and TLR rates 
(DES 9.2% versus BMS 20% (P = 0.06).117  
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The IDEAS (Infra-popliteal Drug- Eluting Angioplasty Versus Stenting) Randomized 
Controlled Trial115 compared a paclitaxel DCB (IN.PACT Amphirion (Medtronic, Brescia, Italy) to 
DES in long (>70 mm) infra-popliteal lesions in patients with Rutherford classes 3 to 6.  Fifty 
patients were randomized to infra-popliteal DCB angioplasty (25 arteries in 25 limbs; PCB group) 
or primary DES placement (30 arteries in 27 limbs; DES group).  At 6 months, the angiographic 
restenosis rate was significantly lower in DES (28% versus 57.9% in DCB; p = 0.046).  There were 
no significant differences with regard to TLR (7.7% in DES versus 13.6% in DCB; p = 0.65). In this 
comparison for longer below knee lesions, DES were associated with significantly reduced 
restenosis rates at 6 months compared to DCB.   
The PADI (Percutaneous transluminal Angioplasty versus Drug eluting stents for Infra-
popliteal lesions) trial was designed to compare the performance of paclitaxel-eluting DESs and 
PTA-BMS of infra-popliteal lesions in a population consisting solely of CLI patients. 118 Recently, the 
five-year follow data were published confirming the long-term advantage of coronary paclitaxel 
DES over a PTA with provisional BMS stenting (PTA-BMS) for RC class ≥4 patients with infra-
popliteal lesions. The 5-year clinical outcomes of amputation and event-free survival (survival free 
from major amputation or reintervention) the DES arm was superior to the PTA-BMS group (31.8% 
versus 20.4%, P=0.043; and 26.2% versus 15.3%, P=0.041, respectively). Survival rates were 
comparable. The results showed higher preserved patency rates after DESs than after PTA-BMS at 
1, 3, and 4 years of follow-up. These data, including several meta-analyses, provide convincing 
evidence (Class 1, LOE B) favoring infra-popliteal DES over PTA and BMS for 1) improved patency, 
2) reduced re-interventions, 3) reduced amputation, and 4) improved event-free survival. 117,119-123    
Drug-Coated Balloons: The evidence supporting the use of DCB for infra-popliteal lesions is 
less certain.  The DEBATE-BTK79 (Drug-Eluting Balloon in Peripheral Intervention for Below the 
Knee Angioplasty Evaluation) trial randomized 158 infra-popliteal lesions in diabetic patients with 
CLI to either DCB (In.Pact Amphirion, Medtronic, Minneapolis, MN, USA) or PTA.  The mean lesion 
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length was 129 ± 83 mm, significantly (~100 mm) longer than those in the infra-popliteal DES 
randomized trials. The primary endpoint, restenosis at 1 year occurred in 27% of DCB and 74.3% of 
PTA groups (P < 0.001).  Twelve-month major adverse events occurred less frequently in the DCB 
(31%) than in the PTA (51%) group (p=0.02), driven mainly by a reduction in TLR and improved 
ulcer healing.  However, there was no difference in the rate of amputation, limb salvage, or 
mortality between the groups. 
The In.Pact Deep CLI trial126 DCB resulted in this balloon (In.Pact Amphirion, Medtronic, 
Minneapolis, MN, USA) being withdrawn from the market worldwide by the sponsor. The trial 
enrolled 358 CLI patients with infra-popliteal lesions and randomized them 2:1 to DCB and PTA, 
respectively. The primary efficacy endpoints were not different for 1) 12-month late lumen loss for 
the DCB (0.61 ± 0.78 mm) group or the PTA (0.62 ± 0.78, p=0.95) group, and 2) the clinically driven 
TLR for the DCB (17.7%) group or the PTA (15.8%, p=0.66) group. There was a non-significant 
trend toward higher amputation rates in the DCB (8.8%) compared to the PTA group (3.6%, 
P=0.08).  
There are no data to suggest that procedures on infra-popliteal arteries should be 
performed to prevent CLI. This is confirmed in the recent ACC/AHA guidelines that state: 
“Endovascular procedures should not be performed in patients with PAD solely to prevent 
progression to CLI.” 54  This is based on data showing that though feared, the rate of progression to 
CLI and/or amputation remains relatively low. 127-129  
 
Conclusion 
 The Society of Cardiovascular Angiography and Interventions, conducted an appropriate 
use review of common clinical presentations for PAD to determine the appropriateness for devices 
and strategies for revascularization. This document summarizes new information updating the 
prior AUC documents published for aorto-iliac, femoral-popliteal, infra-popliteal and renal arterial 
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circulation.1-4   The intent is to improve clinical decision making by practitioners, to improve our 
patients' understanding of the potential risks and benefits of intervention, and to provide 
interventionalists with an updated review of the current literature regarding the most recent 
advances in the field of EVT.  
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Figure Legends: 
Figure 1: Upper panel: Peak Walking Time (PWT): Patients with 18-month follow-up visit only.  
Lower panel: Claudication Onsent Time (COT): Patients with 18-month follow-up visit only. (Figure 
1 reproduced with permission)57 
Figure 2: Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease 
(TASC) classification of aortoiliac lesions. AAA, abdominal aortic aneurysm CFA, common femoral 
artery; CIA, common iliac artery; EIA, external iliac artery (Figure 1, reproduced with permission).33 
Figure 3: Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease 
(TASC) classification of femoral popliteal lesions. CFA, common femoral artery; SFA, superficial 
femoral artery (Figure 2, reproduced with permission). 33  
Figure 4. Trans-Atlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease 
(TASC) classification of infra-popliteal lesions. The unshaded area represents the target lesion; area 
inside the shaded rectangle represents typical background disease (Figure 3, reproduced with 
permission).
33
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Table 1. Assessing Renal Artery Stenosis Significance 
 
 
Angiographic 
Stenosis Severity*  
Physiologic Testing Significance 
<50% None Mild 
50-70% None Indeterminate 
50-70% with Resting or hyperemic mean pressure 
gradient** ≥10mmHg 
Significant 
50-70% with Resting or hyperemic systolic Pressure 
Gradient ≥20mmHg† 
Significant 
50-70% with Renal Pd/Pa ≤ 0.8† Significant 
≥70% None Significant 
* = visual estimation.  ** = translesional gradient measured with a non-obstructive catheter, 
ie ≤ 4 fr or with an 0.014-in pressure wire (Pd/Pa). † Hyperemia may be induced with 
intrarenal bolus of papaverine 30mg or dopamine at 50µg/kg.  Excludes patients who have 
been on hemodialysis ≥ 3 months and those with non-viable kidneys, i.e. a pole to pole 
length of ≤ 7 cm. 
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Table 3. Summary of AHA/ACC Guideline recommendations for renal intervention 9. 
Resistant Hypertension Ischemic Nephropathy Cardiac Disturbances 
RAS with accelerated, 
resistant, or malignant 
hypertension, hypertension 
with unilateral small kidney, 
and hypertension with 
medication intolerance. 
(Class IIa, LOE B). 
CKD with bilateral significant 
RAS or RAS of a solitary 
kidney (Class IIa; LOE B). 
Hemodynamically significant 
RAS with recurrent 
unexplained heart failure or 
sudden explained pulmonary 
edema. (Class I, LOE B) 
 CKD with unilateral 
significant RAS (Class IIb; 
LOE B) 
RAS with unstable angina. 
(Class IIa, LOE B) 
 Asymptomatic unilateral, 
bilateral, or a solitary viable 
kidney with 
hemodynamically significant 
RAS. (Class IIb; LOE C) 
 
RAS = renal artery stenosis; CKD = chronic kidney disease; LOE = level of evidence 
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